Myelofibrosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
==Medical therapy== | ==Medical therapy== | ||
*Asymptomatic low-risk patients should be followed with a watchful waiting approach. The development of [[anemia|symptomatic anemia]], [[leukocytosis|marked leukocytosis]], [[night sweats|drenching night sweats]], [[weight loss]], [[fever]], or [[splenomegaly|symptomatic splenomegaly]] would warrant therapeutic intervention.<ref name=treatmentoverviewofmyelofibrosis1>Treatment overview of primary myelofibrosis. National cancer institute 2016. http://www.cancer.gov/types/myeloproliferative/hp/chronic-treatment-pdq#section/_9. Accessed on March 10, 2016</ref> | |||
==References== | ==References== | ||
Revision as of 15:30, 10 March 2016
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis medical therapy |
|
Risk calculators and risk factors for Myelofibrosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Medical therapy
- Asymptomatic low-risk patients should be followed with a watchful waiting approach. The development of symptomatic anemia, marked leukocytosis, drenching night sweats, weight loss, fever, or symptomatic splenomegaly would warrant therapeutic intervention.[1]
References
- ↑ Treatment overview of primary myelofibrosis. National cancer institute 2016. http://www.cancer.gov/types/myeloproliferative/hp/chronic-treatment-pdq#section/_9. Accessed on March 10, 2016